A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GALVOKIMIG IN ADULT STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522578-35-00

Enrollment

Registered

2026-03-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

Percentage of participants with Eczema Area and Severity Index (EASI)75 response at Week 16

Detailed description

Percentage of Participants with validated Investigator Global Assessment (vIGA) response at Week 16, Change from Baseline in weekly averaged Peak Pruritus Numerical Rating Scale (PP-NRS) at Week 16, Incidence of Treatment-Emergent (TE) Adverse Events (AE), Incidence of TE Serious Adverse Events (SAEs)

Interventions

DRUGPlacebo matching Test 0.9% sodium chloride solution for injection

DRUGGalvokimig

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of participants with Eczema Area and Severity Index (EASI)75 response at Week 16	—

Secondary

Measure	Time frame
Percentage of Participants with validated Investigator Global Assessment (vIGA) response at Week 16, Change from Baseline in weekly averaged Peak Pruritus Numerical Rating Scale (PP-NRS) at Week 16, Incidence of Treatment-Emergent (TE) Adverse Events (AE), Incidence of TE Serious Adverse Events (SAEs)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 11, 2026